283 related articles for article (PubMed ID: 26434609)
1. VRE and VSE Bacteremia Outcomes in the Era of Effective VRE Therapy: A Systematic Review and Meta-analysis.
Prematunge C; MacDougall C; Johnstone J; Adomako K; Lam F; Robertson J; Garber G
Infect Control Hosp Epidemiol; 2016 Jan; 37(1):26-35. PubMed ID: 26434609
[TBL] [Abstract][Full Text] [Related]
2. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.
Bhavnani SM; Drake JA; Forrest A; Deinhart JA; Jones RN; Biedenbach DJ; Ballow CH
Diagn Microbiol Infect Dis; 2000 Mar; 36(3):145-58. PubMed ID: 10729656
[TBL] [Abstract][Full Text] [Related]
3. Enterococcus faecium bacteremia: does vancomycin resistance make a difference?
Stosor V; Peterson LR; Postelnick M; Noskin GA
Arch Intern Med; 1998 Mar; 158(5):522-7. PubMed ID: 9508230
[TBL] [Abstract][Full Text] [Related]
4. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation.
Vydra J; Shanley RM; George I; Ustun C; Smith AR; Weisdorf DJ; Young JA
Clin Infect Dis; 2012 Sep; 55(6):764-70. PubMed ID: 22693346
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of vancomycin-variable Enterococcus faecium (VVE) among vanA-positive sterile site isolates and patient factors associated with VVE bacteremia.
Kohler P; Eshaghi A; Kim HC; Plevneshi A; Green K; Willey BM; McGeer A; Patel SN;
PLoS One; 2018; 13(3):e0193926. PubMed ID: 29566004
[TBL] [Abstract][Full Text] [Related]
6. Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.
Chuang YC; Lin HY; Chen PY; Lin CY; Wang JT; Chen YC; Chang SC
Clin Infect Dis; 2017 Apr; 64(8):1026-1034. PubMed ID: 28329222
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome.
Han SH; Chin BS; Lee HS; Jeong SJ; Choi HK; Kim CO; Yong D; Choi JY; Song YG; Lee K; Kim JM
J Infect; 2009 Mar; 58(3):182-90. PubMed ID: 19233476
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin-resistant enterococcal bacteremia pharmacotherapy.
Patel R; Gallagher JC
Ann Pharmacother; 2015 Jan; 49(1):69-85. PubMed ID: 25352037
[TBL] [Abstract][Full Text] [Related]
9. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis.
DiazGranados CA; Zimmer SM; Klein M; Jernigan JA
Clin Infect Dis; 2005 Aug; 41(3):327-33. PubMed ID: 16007529
[TBL] [Abstract][Full Text] [Related]
10. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.
Chuang YC; Wang JT; Lin HY; Chang SC
BMC Infect Dis; 2014 Dec; 14():687. PubMed ID: 25495779
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis.
Eichel VM; Last K; Brühwasser C; von Baum H; Dettenkofer M; Götting T; Grundmann H; Güldenhöven H; Liese J; Martin M; Papan C; Sadaghiani C; Wendt C; Werner G; Mutters NT
J Hosp Infect; 2023 Nov; 141():119-128. PubMed ID: 37734679
[TBL] [Abstract][Full Text] [Related]
13. Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort.
Butler AM; Olsen MA; Merz LR; Guth RM; Woeltje KF; Camins BC; Fraser VJ
Infect Control Hosp Epidemiol; 2010 Jan; 31(1):28-35. PubMed ID: 19951200
[TBL] [Abstract][Full Text] [Related]
14. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization.
Cheah AL; Spelman T; Liew D; Peel T; Howden BP; Spelman D; Grayson ML; Nation RL; Kong DC
Clin Microbiol Infect; 2013 Apr; 19(4):E181-9. PubMed ID: 23398607
[TBL] [Abstract][Full Text] [Related]
15. Clinical manifestations, characteristics, and outcome of infections caused by vancomycin-resistant enterococci at a tertiary care center in Lebanon: A case-case-control study.
Abi Frem J; Ghanem M; Doumat G; Kanafani ZA
J Infect Public Health; 2023 May; 16(5):741-745. PubMed ID: 36958169
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients.
Britt NS; Potter EM; Patel N; Steed ME
Clin Infect Dis; 2015 Sep; 61(6):871-8. PubMed ID: 26063715
[TBL] [Abstract][Full Text] [Related]
17. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.
Cunha BA; Mickail N; Eisenstein L
Heart Lung; 2007; 36(6):456-61. PubMed ID: 18005808
[TBL] [Abstract][Full Text] [Related]
18. The Risk Factors, Costs, and Survival Analysis of Invasive VRE Infections at a Medical Center in Eastern Taiwan.
Jiang HL; Zhou Z; Wang LS; Fang Y; Li YH; Chu CI
Int J Infect Dis; 2017 Jan; 54():18-24. PubMed ID: 27836794
[TBL] [Abstract][Full Text] [Related]
19. Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia.
Cheah AL; Peel T; Howden BP; Spelman D; Grayson ML; Nation RL; Kong DC
BMC Infect Dis; 2014 Jun; 14():353. PubMed ID: 24973797
[TBL] [Abstract][Full Text] [Related]
20. Patient- and hospital-level predictors of vancomycin-resistant Enterococcus (VRE) bacteremia in Ontario, Canada.
Johnstone J; Chen C; Rosella L; Adomako K; Policarpio ME; Lam F; Prematunge C; Garber G;
Am J Infect Control; 2018 Nov; 46(11):1266-1271. PubMed ID: 29903421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
